TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT ID: NCT06207032
Last Updated: 2025-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2024-06-26
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
NCT03892096
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
NCT06163534
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT04354064
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 001: KRAS mutated CRC
No intervention.
No interventions assigned to this group
Cohort 002: KRAS mutated PDAC
No intervention.
No interventions assigned to this group
Cohort 003: KRAS mutated NSCLC
No intervention.
No interventions assigned to this group
Cohort 004: Gastric 1L Plus
No intervention.
No interventions assigned to this group
Cohort 005: mCRPC 1L Plus
No intervention.
No interventions assigned to this group
Cohort 006: Pan Tumor ADCs
No intervention.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing to participate in the research
3. Able to provide informed consent
4. Must be diagnosed with cancer
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tempus AI
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michelle Ting-Lin, MD
Role: STUDY_DIRECTOR
Tempus AI, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Oncology
Birmingham, Alabama, United States
PIH Health Whittier Hospital & PIH Health Physicians
Whittier, California, United States
Eastern CT and Hematology and Oncology Associates
Norwich, Connecticut, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Morehouse
Atlanta, Georgia, United States
Southern Illinois Healthcare
Carterville, Illinois, United States
Hope and Healing Cancer Services
Hinsdale, Illinois, United States
Cancer Care Specialists of Illinois
O'Fallon, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Northwest Oncology and Hematology
Rolling Meadows, Illinois, United States
Fort Wayne
Fort Wayne, Indiana, United States
Goshen Center for Cancer Care
Goshen, Indiana, United States
St. Claire Healthcare
Morehead, Kentucky, United States
Frederick Health Regional System
Frederick, Maryland, United States
Southcoast Centers for Cancer Care
Fairhaven, Massachusetts, United States
Hannibal Regional Healthcare System, Inc.
Hannibal, Missouri, United States
Lake Regional Health
Osage Beach, Missouri, United States
Oncology Hematology Associates
Springfield, Missouri, United States
Hope Cancer Care of Nevada
Las Vegas, Nevada, United States
Cancer Care Specialists - Reno
Reno, Nevada, United States
New Jersey Cancer Center
Belleville, New Jersey, United States
Regional Cancer Care Associates
Belleville, New Jersey, United States
Hematology Oncology Associates of Central NY
East Syracuse, New York, United States
Cayuga Medical Center
Ithaca, New York, United States
Sanford Roger Maris Cancer Center (Fargo)
Fargo, North Dakota, United States
Taylor Cancer Research Center
Maumee, Ohio, United States
Cancer Care Associates of York
York, Pennsylvania, United States
Pan American Center for Oncology Trials
Rio Piedras, Puerto Rico, Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mehdi Moezi
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Thomas M. Pharma and the benefits of Real World Data. Drug Discovery World (DDW). Published November 4, 2021. Accessed May 5, 2023. https://www.ddw-online.com/trends-analysis-pharma-and-the-benefits-of-real-world-data-13702-202111/
Office of the Commissioner. Oncology Real World Evidence Program. U.S. Food and Drug Administration. Accessed May 5, 2023. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-real-world-evidence-program
Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3.
Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023 Feb;11(2):e005344. doi: 10.1136/jitc-2022-005344.
Grayson N. Real-world data can help make better drugs and do it faster. STAT. Published May 2, 2018. Accessed May 5, 2023. https://www.statnews.com/2018/05/02/real-world-data-drug-development/
Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; Draft guidance for industry. Accessed September 8, 2023. https://www.fda.gov/media/158072/
Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, Sorrells S, Baker T, Chang A, Michuda J, Iguartua C, MacNeil S, Shah K, Ellis P, Yeatts K, Mahon B, Taxter T, Bontrager M, Khan A, Huether R, Lefkofsky E, White KP. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019 Mar 22;10(24):2384-2396. doi: 10.18632/oncotarget.26797. eCollection 2019 Mar 22.
Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019 Nov;37(11):1351-1360. doi: 10.1038/s41587-019-0259-z. Epub 2019 Sep 30.
Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac'hmeur A, McKinnon KE, Perera J, Zhu W, Dowlati A, White KP, Tell R, Beaubier N. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021 Jul 2;5(1):63. doi: 10.1038/s41698-021-00202-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00076336
Identifier Type: OTHER
Identifier Source: secondary_id
TP-CA-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.